Hua Medicine (Shanghai) Ltd. (2552.HK)

HKD 1.46

(0.69%)

Market Cap (In HKD)

1.43 Billion

Revenue (In HKD)

76.61 Million

Net Income (In HKD)

-211.23 Million

Avg. Volume

1.19 Million

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.03-2.55
PE
-
EPS
-
Beta Value
1.417
ISIN
KYG4644K1022
CUSIP
G4644K102
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Li Chen Ph.D.
Employee Count
-
Website
https://www.huamedicine.com
Ipo Date
2018-09-14
Details
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.